Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 Feb 2024 Results assessing Biomarker of Staphylococcus aureus abundance and Severity of Atopic Dermatitis presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
28 Feb 2022 Primary endpoint has been met. (Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up), as per Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
28 Feb 2022 Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com